We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Exosome Diagnostics and DxS Collaborate to Develop Blood Based Tests for Key Cancer Mutations
News

Exosome Diagnostics and DxS Collaborate to Develop Blood Based Tests for Key Cancer Mutations

Exosome Diagnostics and DxS Collaborate to Develop Blood Based Tests for Key Cancer Mutations
News

Exosome Diagnostics and DxS Collaborate to Develop Blood Based Tests for Key Cancer Mutations

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Exosome Diagnostics and DxS Collaborate to Develop Blood Based Tests for Key Cancer Mutations"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Exosome Diagnostics, Inc. and DxS Ltd. have announced that they will collaborate on the development of blood based companion diagnostics for key cancer gene mutations, such as KRAS, BRAF and EGFR.

The collaboration will use DxS’ Scorpions® real-time PCR Mutation Test Kits in conjunction with ExosomeDX’s xOSÔ technology which harvests high-quality nucleic acids from blood exosomes.

The collaboration will initially focus on developing blood-based measurement of KRAS, BRAF, EGFR and other key mutations for predicting patient response to targeted therapies. Blood based mutation measurement is particularly valuable in circumstances where tissue bioavailability is limited such as in lung, pancreatic and ovarian cancers.

Exosomes are small microvesicles precipitously shed by all solid tumors into blood. They contain virtually the entire cancer tumor transcriptome.

In studies, ExosomeDX has identified over 21,000 mRNA and 1,100 miRNA in circulating tumor derived exosomes, all protected in the exosome lipid bi-layer from any blood-based RNase. Initial findings were published in the December 2008 issue of Nature Cell Biology.

“There are over 180 companies investigating over 370 different molecular targeted cancer therapies, many of which will require high-quality, molecular companion diagnostics” said James McCullough, Chief Executive Officer Exosome Diagnostics. “Teaming with the world leader in this space is a critical step in providing a solution for pharmaceutical companies, researchers and clinicians to measure the key mutations DxS Scorpion probes target directly from blood.”

“Combining the ability to pull high-quality mutations from a simple blood draw with the unparalleled sensitivity and specificity of our Scorpion assays will provide our pharmaceutical and research customers with an ideal solution in personalized medicine” said Dr. Stephen Little, Chief Executive Officer of DxS.
Advertisement